



Ki-67 IHC MIB-1 pharmDx (Dako Omnis)

A More Complete Picture.

Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is now available in the U.S. as an aid in identifying patients with early breast cancer at high risk of disease recurrence for whom adjuvant treatment with Verzenio® (abemaciclib) in combination with endocrine therapy is being considered.



For In Vitro Diagnostic Use. For countries outside of the United States, see the local Verzenio product label for approved prescription information to guide therapy.

© Agilent Technologies, Inc. 2021

D69369/2021NOV18